E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary Arterial Hypertension |
Ipertensione arteriosa polmonare |
|
E.1.1.1 | Medical condition in easily understood language |
Pulmonary Arterial Hypertension |
Ipertensione arteriosa polmonare |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to provide UT-15C for eligible subjects who participated in TDE-PH-310 |
Fornire UT-15C ai soggetti idonei che hanno partecipato allo studio TDE-PH-310 |
|
E.2.2 | Secondary objectives of the trial |
1) To assess the long-term safety of UT-15C 2) To assess the effect of continued long-term therapy with UT-15C on exercise capacity (6MWT/Borg dyspnea score), WHO functional class, and plasma concentrations of NT-proBNP (Week 48 only) |
1) Verificare la sicurezza a lungo termine di UT-15C orale 2) Verificare l’effetto di una terapia a lungo termine continua con UT-15C sulla capacità di esercizio (distanza percorsa a piedi in sei minuti [six minute walk distance, 6MWD]/punteggio della dispnea su Borg), classe funzionale dell’Organizzazione mondiale della sanità (OMS), e frammento N-terminale del pro-peptide natriuretico cerebrale (N-terminal pro-brain natriuretic peptide, NT-proBNP) (solo alla Settimana 48) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.The subject voluntarily provides informed consent to participate in the study. 2.The subject participated in study TDE-PH-310 and met the definition of clinical worsening (as specified in protocol TDE PH 310), remained on study drug, was compliant with study procedures and assessments during the TDE-PH-310 study or was currently enrolled in that study at the time the study was discontinued by the Sponsor. 3.Women of childbearing potential (WOCBP) must practice true abstinence from intercourse or use two different forms of highly effective contraception for the duration of the study, and for at least 30 days after discontinuing study medication. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device (IUD), or (4) partner vasectomy. For women of childbearing potential, a negative urine pregnancy test is required at Baseline (study entry) prior to initiating study medication. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea for at least 12 consecutive months]. 4.Males participating in the study must use a condom during the length of the study, and for at least 48 hours after their last dose of study medication. |
1. Il soggetto fornisce volontariamente il consenso informato a partecipare allo studio.
2. Il soggetto ha partecipato allo studio TDE-PH-310 e ha soddisfatto la definizione di peggioramento clinico (secondo quanto specificato nel protocollo TDE PH 310), ha proseguito l’assunzione del farmaco in studio, si è attenuto alle procedure e alle valutazioni dello studio durante lo studio TDE-PH-310 oppure è stato arruolato attualmente in tale studio nel momento in cui lo studio è stato interrotto dallo Sponsor.
3. Le donne potenzialmente fertili (women of childbearing potential, WOCBP) devono astenersi completamente dai rapporti sessuali oppure utilizzare due diverse forme di contraccezione altamente efficaci per l’intera durata dello studio e per almeno 30 giorni dopo l’interruzione del farmaco in studio. Le forme medicalmente accettabili di contraccezione efficace comprendono: (1) contraccettivi ormonali approvati (quali pillole anticoncezionali), (2) metodi di barriera (quali preservativo o diaframma) utilizzati unitamente a spermicida, (3) un dispositivo intrauterino (IUD) o (4) vasectomia del partner. Per le donne potenzialmente fertili è richiesto un test di gravidanza sulle urine con esito negativo al Basale (ingresso nello studio) prima di iniziare l’assunzione del farmaco in studio. Per WOCBP si intende qualsiasi persona di sesso femminile che abbia avuto il menarca e che non sia stata sottoposta a sterilizzazione chirurgica con esito positivo (isterectomia, legamento bilaterale delle tube oppure ovariectomia bilaterale) o che non sia in fase di post-menopausa (definita come amenorrea per almeno 12 mesi consecutivi).
4. I soggetti di sesso maschile che partecipano allo studio devono utilizzare il preservativo per l’intera durata dello studio e per almeno 48 ore dopo l’assunzione dell’ultima dose di farmaco in studio. |
|
E.4 | Principal exclusion criteria |
1.The subject is pregnant or lactating. 2.The subject is receiving infused or inhaled prostacyclin therapy. 3.The subject was prematurely discontinued from study TDE-PH-310 for reasons other than a clinical worsening event. 4.The subject developed a concurrent illness or condition during the conduct of TDE PH 310 which, in the opinion of the investigator, would represent a risk to overall health if they enrolled in this study. |
1. Il soggetto è in gravidanza o sta allattando al seno.
2. Il soggetto sta ricevendo una terapia a base di prostacicline per infusione o inalazione.
3. Il soggetto ha interrotto precocemente la partecipazione allo studio TDE-PH-310 per motivi diversi da un evento di peggioramento clinico.
4. Il soggetto ha sviluppato una patologia o condizione concomitante durante la conduzione dello studio TDE PH 310 che, a opinione dello sperimentatore, rappresenterebbe un rischio alla salute generale del soggetto se venisse arruolato in questo studio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical assessments - Efficacy and Safety |
Valutazioni cliniche - Efficacia e Sicurezza |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Efficacy: 6MWT- baseline, week 6, week 12 and every 12 weeks thereafter, and at study termination visit Borg Dysphea Score- Following each 6MWT WHO functional Class- baseline, week 6, week 12 and every 12 weeks thereafter, and at study termination visit N-terminal pro BNP- Baseline and week 48 Safety: Vital signs- baseline and at all subsequent protocol-required visits Physical examination- Baseline and study termination visit Clinical Laboratory Assessments- Baseline, week 12, week 24 and at every other follow-up visit thereafter, and at the study termination visit Adverse event assessments- captured from the time the ICF is signed and should be followed for up to 30 days after completion of the study termination visit |
Efficacia:
6MWT - Basale, sett. 6, 12 e successivamente ogni 12, nonché alla visita conclusiva dello studio
Punteggio di Borg per valutare la dispnea - Dopo ogni 6MWT
Classe funzionale dell’OMS - Basale, sett. 6, 12 e successivamente ogni 12, nonché alla visita conclusiva dello studio
pro BNP N-terminale - Basale e sett. 48
Sicurezza:
Parametri vitali - Basale e tutte le visite successive richieste dal protocollo
Esame obiettivo - Basale e visita di conclusione dello studio
Valutazioni cliniche di laboratorio - Basale, sett. 12, 24 e quindi ad ogni visita di follow-up successiva, nonché alla visita conclusiva dello studio
Valutazione degli eventi avversi - Acquisiti dal momento in cui viene firmato ICF e devono essere seguiti fino a 30 gg dalla visita conclusiva |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 29 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Canada |
Israel |
Korea, Republic of |
Mexico |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will continue until either oral UT-15C becomes available within the respective territories or the study is discontinued by the sponsor |
Lo studio proseguirà fino a che UT-15C diventa disponibile sul mercato all’interno dei rispettivi territori o finché lo studio viene interrotto dallo sponsor |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |